UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunological Responses to Exogenous Insulin

Endocrine reviews, 2007-10, Vol.28 (6), p.625-652

2007

Volltextzugriff (PDF)

Glucocorticoid-induced adrenal insufficiency

JAMA : the journal of the American Medical Association, 1999-08, Vol.282 (7), p.671

Krasner, A S

1999

Volltextzugriff (PDF)

Development and evaluation of the Acromegaly Symptom Diary

Journal of patient-reported outcomes, 2023-02, Vol.7 (1), p.15-15, Article 15

2023

Volltextzugriff (PDF)

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes

Diabetes care, 2010-01, Vol.33 (1), p.116-120

2010

Volltextzugriff (PDF)

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism

The journal of clinical endocrinology and metabolism, 2018-02, Vol.103 (2), p.722-731

2018

Volltextzugriff (PDF)

Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review

Journal of medical economics, 2019-11, Vol.22 (11), p.1141-1152

2019

Volltextzugriff (PDF)

Insulin antibodies with pulmonary delivery of insulin

Diabetes technology & therapeutics, 2007-06, Vol.9 Suppl 1 (s1), p.S102-S-110

2007

Volltextzugriff (PDF)

ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly

The journal of clinical endocrinology and metabolism, 2023-05, Vol.108 (5), p.e148-e159

2023

Volltextzugriff (PDF)

Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)

The journal of clinical endocrinology and metabolism, 2020-10, Vol.105 (10), p.e3557-e3565

2020

Volltextzugriff (PDF)

Development of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas

Journal of diabetes science and technology, 2015-01, Vol.9 (1), p.8-16

2015

Volltextzugriff (PDF)

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

The journal of clinical endocrinology and metabolism, 2024-06

2024

Volltextzugriff (PDF)

Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism

Advances in therapy, 2019-08, Vol.36 (8), p.1999-2009

2019

Volltextzugriff (PDF)

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers

Pituitary, 2022-04, Vol.25 (2), p.328-339

2022

Volltextzugriff (PDF)

SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist

Journal of the Endocrine Society, 2023-10, Vol.7 (Supplement_1)

2023

Volltextzugriff (PDF)

SAT626 The Use Of Salivary Cortisol Measurement By Mass Spectrometry To Identify Low Serum Cortisol Values In Healthy Volunteers Receiving CRN04894, A Melanocortin 2 Receptor (MC2R) Antagonist

Journal of the Endocrine Society, 2023-10, Vol.7 (Supplement_1)

2023

Volltextzugriff (PDF)

Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy

Current medical research and opinion, 2008-11, Vol.24 (11), p.3073-3083

2008

Volltextzugriff (PDF)

Antibody Response to Inhaled Insulin in Patients with Type 1 or Type 2 Diabetes. An Analysis of Initial Phase II and III Inhaled Insulin (Exubera) Trials and a Two-Year Extension Trial

The journal of clinical endocrinology and metabolism, 2005-06, Vol.90 (6), p.3287-3294

2005

Volltextzugriff (PDF)

Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses

Clinical therapeutics, 2017-10, Vol.39 (10), p.2096-2102

2017

Volltextzugriff (PDF)

COMPARISON OF 3-YEAR ESTIMATED GLOMERULAR FILTRATION RATES BETWEEN RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) (RHPTH[1-84])-TREATED PATIENTS WITH CHRONIC HYPOPARATHYROIDISM AND A HISTORICAL CONTROL COHORT

Endocrine practice, 2018-04, Vol.24, p.111-111

2018

Volltextzugriff (PDF)

Abstract #511 Comparison of 3-Year Estimated Glomerular Filtration Rates Between Recombinant Human Parathyroid Hormone (1-84) (RHPTH[1-84])-Treated Patients with Chronic Hypoparathyroidism and a Historical Control Cohort

Endocrine practice, 2018-04, Vol.24, p.111

2018

Volltextzugriff (PDF)

Anaplastic pseudothyroiditis

Clinical endocrinology (Oxford), 2002-04, Vol.56 (4), p.553-555

2002

Volltextzugriff (PDF)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands

Journal of the Endocrine Society, 2023-10, Vol.7 (Supplement_1)

2023

Volltextzugriff (PDF)

Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A524-A524

2021

Volltextzugriff (PDF)

The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin

Diabetes care, 2005-09, Vol.28 (9), p.2161-2169

2005

Volltextzugriff (PDF)

A review of a family of ultra-rapid-acting insulins: formulation development

Journal of diabetes science and technology, 2012-07, Vol.6 (4), p.786-796

2012

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(67)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(84)

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(30)
Humans
(29)
Female
(16)
Endocrinology & Metabolism
(14)
Male
(14)
Adult
(12)
Biological And Medical Sciences
(12)
Medical Sciences
(11)
Middle Aged
(9)
Insulin - Administration & Dosage
(8)
Administration, Inhalation
(7)
Diabetes Mellitus, Type 1 - Drug Therapy
(7)
Insulin - Therapeutic Use
(7)
Social Sciences
(7)
Aged
(6)
Clinical Trials
(6)
Hypoglycemic Agents - Administration & Dosage
(6)
Hypoparathyroidism
(6)
Patients
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immunological Responses to Exogenous Insulin

Glucocorticoid-induced adrenal insufficiency

Development and evaluation of the Acromegaly Symptom Diary

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism

Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review

Insulin antibodies with pulmonary delivery of insulin

ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly

Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)

Development of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers

SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist

SAT626 The Use Of Salivary Cortisol Measurement By Mass Spectrometry To Identify Low Serum Cortisol Values In Healthy Volunteers Receiving CRN04894, A Melanocortin 2 Receptor (MC2R) Antagonist

Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy

Antibody Response to Inhaled Insulin in Patients with Type 1 or Type 2 Diabetes. An Analysis of Initial Phase II and III Inhaled Insulin (Exubera) Trials and a Two-Year Extension Trial

Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses

COMPARISON OF 3-YEAR ESTIMATED GLOMERULAR FILTRATION RATES BETWEEN RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) (RHPTH[1-84])-TREATED PATIENTS WITH CHRONIC HYPOPARATHYROIDISM AND A HISTORICAL CONTROL COHORT

Abstract #511 Comparison of 3-Year Estimated Glomerular Filtration Rates Between Recombinant Human Parathyroid Hormone (1-84) (RHPTH[1-84])-Treated Patients with Chronic Hypoparathyroidism and a Historical Control Cohort

Anaplastic pseudothyroiditis

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands

Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly

The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin

A review of a family of ultra-rapid-acting insulins: formulation development

Suchergebnisse filtern